News Takeda Pharmaceutical Company Limited Deutsche Boerse AG

Equities

TKDA

US8740602052

Real-time Estimate Tradegate Other stock markets 06:51:11 2024-06-17 EDT			5-day change	1st Jan Change
12.3 ^EUR	+2.50%		-2.44%	-4.76%

02:13pm	Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	MT
02:00pm	Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	08:13am	MT
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints	08:00am	MT
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies	07:32am	DJ
Takeda's seizure drug fails to meet main goal in late-stage studies	07:07am	RE
Takeda Pharmaceutical : Announces Phase 3 Topline Results for Soticlestat (TAK 935) in Patients with Dravet Syndrome and Lennox Gastaut Syndrome Form 6 K	06:50am	PU
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	06:46am	BU
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug	06-14	MT
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)	06-14	BU
Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor	06-14	CI
Takeda Issues New Shares, Disposes of Treasury Shares Under Long-term Incentive Plan for Employees	06-11	MT
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts	06-11	BU
Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long Term Incentive Plan for Company Group Employees Outside of Japan Form 6 K	06-11	PU
Takeda Pharmaceutical Prices Second Hybrid Bonds for 460 Billion Yen	06-10	MT
TAKEDA PHARMACEUTICAL : Form 6 K	06-10	PU
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K	06-07	PU
Former Takeda Employee Pleads Guilty to Defrauding Company	06-06	DJ
Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema	06-06	MT
Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India	06-06	MT
Takeda Pharmaceutical - Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan	06-04	AQ
Transcript : Takeda Pharmaceutical Company Limited - Special Call	06-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Takeda Pharmaceutical Company Limited Deutsche Boerse AG

Equities

TKDA

US8740602052

Summary

Filters